Ishita Drugs & Industries Ltd Stock Price Today (NSE: ISHITADR)
Fundamental Score
Ishita Drugs & Industries Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Ishita Drugs & Industries Ltd share price today is ₹81.46, up +8.76% on NSE/BSE as of 22 June 2026. Ishita Drugs & Industries Ltd (ISHITADR) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹21.59 (Cr). The 52-week high for ISHITADR share price is ₹90.85 and the 52-week low is ₹66.00. At a P/E ratio of 22.26x, ISHITADR is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 8.40% and a debt-to-equity ratio of 0.18.
Ishita Drugs & Industries Ltd Share Price Chart — NSE/BSE Historical Performance
Ishita Drugs & Industries Ltd share price chart: 4.34% return over the past month. 52-week high ₹90.85, 52-week low ₹66.00.
Ishita Drugs & Industries Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹78.78 | ₹81.50 | ₹78.00 | ₹81.46 | 668.00 (Cr) | |
| ₹74.90 | ₹74.90 | ₹74.90 | ₹74.90 | 0.00 (Cr) | |
| ₹82.00 | ₹87.33 | ₹70.00 | ₹74.90 | 1.34K (Cr) | |
| ₹80.34 | ₹80.34 | ₹80.34 | ₹80.34 | 0.00 (Cr) | |
| ₹80.34 | ₹80.34 | ₹80.34 | ₹80.34 | 0.00 (Cr) | |
| ₹80.34 | ₹80.34 | ₹80.34 | ₹80.34 | 0.00 (Cr) | |
| ₹76.00 | ₹87.10 | ₹76.00 | ₹80.34 | 10.00K (Cr) | |
| ₹77.11 | ₹77.50 | ₹77.11 | ₹77.11 | 310.00 (Cr) | |
| ₹79.00 | ₹79.00 | ₹76.00 | ₹77.00 | 4.39K (Cr) | |
| ₹79.10 | ₹79.10 | ₹78.61 | ₹78.61 | 74.00 (Cr) |
Ishita Drugs & Industries Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹74.90 | ₹81.50 | ₹74.90 | ₹81.46 | +8.76% | |
| ₹81.02 | ₹87.33 | ₹70.00 | ₹74.90 | -7.55% | |
| ₹71.00 | ₹85.60 | ₹70.29 | ₹81.02 | +14.11% | |
| ₹71.00 | ₹89.40 | ₹66.12 | ₹69.11 | -2.66% | |
| ₹72.98 | ₹75.85 | ₹67.00 | ₹70.97 | -2.75% | |
| ₹80.89 | ₹89.00 | ₹66.00 | ₹68.38 | -15.47% | |
| ₹70.00 | ₹90.85 | ₹70.00 | ₹80.00 | +14.29% | |
| ₹73.00 | ₹74.87 | ₹68.02 | ₹70.00 | -4.11% | |
| ₹80.00 | ₹81.24 | ₹70.25 | ₹73.00 | -8.75% | |
| ₹74.00 | ₹87.90 | ₹67.00 | ₹81.40 | +10.00% | |
| ₹77.80 | ₹78.80 | ₹70.45 | ₹75.10 | -3.47% | |
| ₹85.00 | ₹85.00 | ₹72.60 | ₹78.60 | -7.53% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Ishita Drugs & Industries Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Ishita Drugs & Industries Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ISHITADR across key market metrics for learning purposes.
Positive Indicators
4 factors identified
Attractive Valuation (P/E: 22.26 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Conservative Debt Levels (D/E: 0.18)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (17.25x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
7 factors identified
Below-Average Return on Equity (8.40%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (9.91%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Profit Decline Concern (-26.32%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-6.12%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Limited Growth History (0.23% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Negative Free Cash Flow (₹-2.37 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Ishita Drugs & Industries Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Ishita Drugs & Industries Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Ishita Drugs & Industries LtdIshita Drugs & ...Selected✓ ISHITADR • 524400 | 29.3/100 | ₹81.46₹81 | ₹21.59₹21.59 | 22.26Average 22.3 Average | 8.40%Poor 8.40% Poor | 9.91%Poor 9.91% Poor | 0.18Excellent 0.2 Excellent | 9.61%Good 9.61% Good | 0.23%Average 0.23% Average | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Ishita Drugs & Industries Ltd PE Ratio History
Historical price-to-earnings ratio for ISHITADR — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹2.50 | ₹92.43 | 37x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Ishita Drugs & Industries Ltd Quarterly Performance
Latest quarterly metrics for ISHITADR — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-6.12%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-26.32%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
0.23%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
9.61%
Compounded annual net profit growth over 5 years
Ishita Drugs & Industries Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for ISHITADR — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Ishita Drugs & Industries Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Ishita Drugs & Industries Ltd (ISHITADR) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Ishita Drugs & Industries Ltd
About ISHITADR (Ishita Drugs & Industries Ltd)
Ishita Drugs & Industries Ltd is a dynamic force in the global pharmaceutical landscape, dedicated to the meticulous development and distribution of high-quality pharmaceutical ing...redients. Specializing in both established and innovative compounds, ISHITADR caters to the diverse needs of pharmaceutical manufacturers worldwide. Their state-of-the-art facilities adhere to stringent international regulatory standards, ensuring consistent product quality and safety. Driven by a commitment to scientific excellence and technological advancement, the company constantly invests in research and development to expand its product portfolio and offer cutting-edge solutions. ISHITADR strives to be a trusted partner, providing reliable and cost-effective ingredients that contribute to improved patient outcomes. The company's core expertise lies in the production of a broad spectrum of essential pharmaceutical materials. This includes vital active pharmaceutical ingredients for various therapeutic areas, alongside specialized fine chemicals crucial for drug formulation. Ishita Drugs & Industries excels in the synthesis of complex molecules and the purification of natural products. Beyond standard offerings, ISHITADR is adept at crafting tailored solutions. The company also takes pride in fostering collaborative relationships, working closely with clients to meet their specific requirements and offering customized product development services. Their dedication to flexibility and customer satisfaction positions them as a valuable asset within the pharmaceutical supply chain. ISHITADR's commitment extends beyond product excellence to encompass sustainable and responsible manufacturing practices. The company prioritizes environmental stewardship, employing eco-friendly processes and minimizing waste generation. With a global perspective, ISHITADR actively seeks opportunities to expand its market presence and forge strategic alliances. The company's unwavering focus on quality, innovation, and customer service makes it a preferred supplier for pharmaceutical manufacturers seeking reliable and trustworthy partners. By consistently delivering high-quality products and adapting to evolving market demands, Ishita Drugs & Industries Ltd remains a prominent player in the pharmaceutical ingredients industry.
Company Details
Key Leadership
ISHITADR Share Price: Frequently Asked Questions
What is the current share price of Ishita Drugs & Industries Ltd?
Ishita Drugs & Industries Ltd (ISHITADR) trades at ₹81.46 on NSE and BSE. Market cap ₹21.59 (Cr). Educational data only.
What is the P/E ratio of Ishita Drugs & Industries Ltd?
Ishita Drugs & Industries Ltd has a P/E of 22.26x vs industry average 31.77x.
What is the Bull Run score for Ishita Drugs & Industries Ltd?
Ishita Drugs & Industries Ltd has a Bull Run score of 29.3/100 based on 25+ financial parameters.
Does Ishita Drugs & Industries Ltd pay dividends?
Ishita Drugs & Industries Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Ishita Drugs & Industries Ltd?
Ishita Drugs & Industries Ltd has ROE of 8.40%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Ishita Drugs & Industries Ltd?
Ishita Drugs & Industries Ltd has debt-to-equity of 0.18.
Is Ishita Drugs & Industries Ltd a good investment?
Bull Run gives Ishita Drugs & Industries Ltd a score of 29.3/100. This is not investment advice — consult a SEBI-registered advisor.